SCHEMBL1718174

SCHEMBL1718174

COc1ccc(-c2cc(C(F)(F)F)n3nc(C(=O)O)cc3n2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.83
KDM4E B2RXH2 7/20 0.83
HSD17B10 Q99714 7/20 0.83
HPGD P15428 6/20 0.83
CASP1 P29466 5/20 0.83
CASP7 P55210 3/20 0.83
MAPT P10636 6/20 0.77
TSHR P16473 3/20 0.77
MAPK1 P28482 2/20 0.77
MEN1 O00255 1/20 0.73
CYP1A2 P05177 1/20 0.73
CYP3A4 P08684 1/20 0.73
CYP2C9 P11712 1/20 0.73
CYP2C19 P33261 1/20 0.73
KMT2A Q03164 1/20 0.73
SMN1; SMN2 Q16637 3/20 0.69
TTR P02766 1/20 0.67
TP53 P04637 3/20 0.66
USP2 O75604 1/20 0.64
ALOX15 P16050 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1718518 0.90 ALDH1A1 (0.82) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL6030712 0.87 KDM4E (0.80) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL4203865 0.87 MAPT (1.00) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL3284626 0.86 KDM4E (1.00) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL14014275 0.86 ALDH1A1 (0.62) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL3278525 0.86 KDM4E (1.00) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL20467506 0.85 ALDH1A1 (0.74) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL20467403 0.85 ALDH1A1 (0.77) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL4212075 0.85 HPGD (1.00) ALDH1A1KDM4EHSD17B10HPGDCASP1
SCHEMBL1719145 0.85 KDM4E (0.80) ALDH1A1KDM4EHSD17B10HPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506196-B1 PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2012-01-18 EP claimed
WO-2010086040-A1 PYRAZOLO-PYRIMIDINES FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA, LTD. (BS) 2010-08-05 WO claimed
CN-118480009-A Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2024-08-13 CN disclosed
US-20230322684-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE CASE WESTERN RESERVE UNIVERSITY 2023-10-12 US disclosed
US-20230322684-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE CASE WESTERN RESERVE UNIVERSITY 2023-10-12 US disclosed
US-11718589-B2 Compositions and methods of modulating short-chain dehydrogenase CASE WESTERN RESERVE UNIVERSITY (US) 2023-08-08 US disclosed
US-11718589-B2 Compositions and methods of modulating short-chain dehydrogenase CASE WESTERN RESERVE UNIVERSITY (US) 2023-08-08 US disclosed
US-20200095206-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2020-03-26 US disclosed
WO-2018145080-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2018-08-09 WO disclosed
WO-2010086040-A1 PYRAZOLO-PYRIMIDINES FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA, LTD. (BS) 2010-08-05 WO disclosed
US-7449488-B2 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2008-11-11 US disclosed
US-7449488-B2 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2008-11-11 US disclosed
WO-2007044410-A1 PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2007-04-19 WO disclosed
US-7196111-B2 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents SCHERING CORPORATION (US) 2007-03-27 US disclosed
US-7196111-B2 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents SCHERING CORPORATION (US) 2007-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200095206-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE HPGD, GCDH, HPGDS ALDH1A1 136/4885KDM4E 3261/4885HSD17B10 21/4885
US-11718589-B2 Compositions and methods of modulating short-chain dehydrogenase HPGD, GCDH, HPGDS ALDH1A1 136/4885KDM4E 3261/4885HSD17B10 21/4885
US-20230322684-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE HPGD, GCDH, HPGDS ALDH1A1 136/4885KDM4E 3261/4885HSD17B10 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.